TABLE 5.
Steady-state pharmacokinetics of silybin A conjugates and silybin B conjugates
Results are shown as geometric means (95% confidence interval), except for Tmax, which is shown as median (minimum, maximum). Data are for n = 6 subjects, except for the HCV 560-mg steady-state cohort where n = 5; one subject was dropped from the pharmacokinetic analysis because of incorrect dosing for pharmacokinetic sampling at steady state on day 8.
| Cohort | PK Parameter | SAconjugates |
SBconjugates |
||
|---|---|---|---|---|---|
| HCV | NAFLD | HCV | NAFLD | ||
| 280 mg | AUC0–8 h (ng · h/ml) | 2048 (1465–2815) | 1297 (652–2271) | 7278 (5633–9287)* | 3962 (2338–6292) |
| Cmax (ng/ml) | 369 (294–459)* | 233 (146–352) | 1294 (1040–1589)* | 750 (563–981) | |
| Tmax (h) | 2 (1, 4) | 2 (0, 4) | 2 (1, 4) | 1.8 (0, 2) | |
| t1/2 (h) | 5 (3–8.3) | 6.8 (2.5–15.5) | 4.3 (2.8–6.3) | 5.1 (1.2–12.7) | |
| 560 mg | AUC0–8 h (ng · h/ml) | 3229 (1618–5348) | 2902 (1403–5163) | 11003 (3244–21,930) | 7745 (4312–12,547) |
| Cmax (ng/ml) | 543 (182–1050) | 529 (287–894) | 2074 (700–4103) | 1592 (927–2600) | |
| Tmax (h) | 2 (0, 4) | 4 (0, 6) | 2 (2, 4) | 3 (0, 4) | |
| t1/2 (h) | 6.2 (3.6–9.3) | 3.6 (2.7–4.7) | 4.1 (2.9–5.6) | 2.8 (1.9–3.9) | |
SA, silymarin A; SB, silymarin B.
*
p < 0.05.